Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

September 20, 2019

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Inflammatory Bowel DiseasesCrohn DiseaseUlcerative Colitis
Interventions
DRUG

2'-Fucosyllactose

Human milk oligosaccharide prebiotic dietary supplement

OTHER

Placebo

Dextrose

Trial Locations (3)

43205

RECRUITING

Nationwide Children's Hospital, Columbus

45229

RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

06106

RECRUITING

Connecticut Children's Medical Center, Hartford

All Listed Sponsors
collaborator

Broad Institute of MIT and Harvard

OTHER

collaborator

University of Cincinnati

OTHER

collaborator

Connecticut Children's Medical Center

OTHER

collaborator

Nationwide Children's Hospital

OTHER

lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT03847467 - Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy | Biotech Hunter | Biotech Hunter